Cite
Roper N, Brown AL, Wei JS, et al. Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer. Cell Rep Med. 2020;1(1)doi: 10.1016/j.xcrm.2020.100007.
Roper, N., Brown, A. L., Wei, J. S., Pack, S., Trindade, C., Kim, C., Restifo, O., Gao, S., Sindiri, S., Mehrabadi, F., El Meskini, R., Ohler, Z. W., Maity, T. K., Venugopalan, A., Cultraro, C. M., Akoth, E., Padiernos, E., Chen, H., Kesarwala, A., Smart, D. K., Nilubol, N., Rajan, A., Piotrowska, Z., Xi, L., Raffeld, M., Panchenko, A. R., Sahinalp, C., Hewitt, S., Hoang, C. D., Khan, J., & Guha, U. (2020). Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer. Cell reports. Medicine, 1(1), . https://doi.org/10.1016/j.xcrm.2020.100007
Roper, Nitin, et al. "Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer." Cell reports. Medicine vol. 1,1 (2020). doi: https://doi.org/10.1016/j.xcrm.2020.100007
Roper N, Brown AL, Wei JS, Pack S, Trindade C, Kim C, Restifo O, Gao S, Sindiri S, Mehrabadi F, El Meskini R, Ohler ZW, Maity TK, Venugopalan A, Cultraro CM, Akoth E, Padiernos E, Chen H, Kesarwala A, Smart DK, Nilubol N, Rajan A, Piotrowska Z, Xi L, Raffeld M, Panchenko AR, Sahinalp C, Hewitt S, Hoang CD, Khan J, Guha U. Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer. Cell Rep Med. 2020 Apr 21;1(1). doi: 10.1016/j.xcrm.2020.100007. PMID: 32483558; PMCID: PMC7263628.
Copy
Download .nbib